JP2020516672A - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
JP2020516672A
JP2020516672A JP2019556274A JP2019556274A JP2020516672A JP 2020516672 A JP2020516672 A JP 2020516672A JP 2019556274 A JP2019556274 A JP 2019556274A JP 2019556274 A JP2019556274 A JP 2019556274A JP 2020516672 A JP2020516672 A JP 2020516672A
Authority
JP
Japan
Prior art keywords
methyl
pyrazol
oxo
pyridin
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516672A5 (https=
Inventor
トルゾス，リニー
マニュエル べタンコート，フアン
マニュエル べタンコート，フアン
カノウニ，トウフィケ
ブレナン ウォレス，マイケル
ブレナン ウォレス，マイケル
ボロアー，アモフ
Original Assignee
セルジーン クオンティセル リサーチ，インク．
セルジーン クオンティセル リサーチ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン クオンティセル リサーチ，インク．, セルジーン クオンティセル リサーチ，インク． filed Critical セルジーン クオンティセル リサーチ，インク．
Publication of JP2020516672A publication Critical patent/JP2020516672A/ja
Publication of JP2020516672A5 publication Critical patent/JP2020516672A5/ja
Priority to JP2023009579A priority Critical patent/JP2023088901A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019556274A 2017-04-18 2018-04-18 治療用化合物 Pending JP2020516672A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023009579A JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762486894P 2017-04-18 2017-04-18
US62/486,894 2017-04-18
US201862657456P 2018-04-13 2018-04-13
US62/657,456 2018-04-13
PCT/US2018/028097 WO2018195155A1 (en) 2017-04-18 2018-04-18 Therapeutic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009579A Division JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Publications (2)

Publication Number Publication Date
JP2020516672A true JP2020516672A (ja) 2020-06-11
JP2020516672A5 JP2020516672A5 (https=) 2021-04-30

Family

ID=63791349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556274A Pending JP2020516672A (ja) 2017-04-18 2018-04-18 治療用化合物
JP2023009579A Pending JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023009579A Pending JP2023088901A (ja) 2017-04-18 2023-01-25 治療用化合物

Country Status (5)

Country Link
US (4) US10617680B2 (https=)
EP (1) EP3612522A4 (https=)
JP (2) JP2020516672A (https=)
TW (2) TWI788343B (https=)
WO (1) WO2018195155A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023088901A (ja) * 2017-04-18 2023-06-27 セルジーン クオンティセル リサーチ，インク． 治療用化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202304303A (zh) * 2021-04-13 2023-02-01 美商富曼西公司 殺真菌之吡啶酮
WO2023275542A1 (en) 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6110557A (ja) * 1984-02-22 1986-01-18 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 新規なピリドン化合物
WO1997001551A1 (en) * 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
WO2007040208A1 (ja) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
JP2007538035A (ja) * 2004-05-18 2007-12-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ピリダジノン誘導体、それらの製造法および医薬としてのそれらの使用
JP2009507758A (ja) * 2005-09-01 2009-02-26 アステラス製薬株式会社 疼痛の治療に用いられるピリダジノン誘導体
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2009028543A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
JP2011526282A (ja) * 2008-06-25 2011-10-06 エンビボ ファーマシューティカルズ インコーポレイテッド １，２−二置換複素環式化合物
JP2012515800A (ja) * 2009-01-26 2012-07-12 インターミューン， インコーポレイテッド 急性心筋梗塞および関連障害を処置するための方法
JP2013517244A (ja) * 2010-01-12 2013-05-16 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
WO2014157569A1 (ja) * 2013-03-28 2014-10-02 武田薬品工業株式会社 複素環化合物
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
JP2016500661A (ja) * 2012-10-02 2016-01-14 インターミューン， インコーポレイテッド 抗線維性ピリジノン
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
WO2016044662A1 (en) * 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
WO2016146738A1 (en) * 2015-03-19 2016-09-22 Glaxosmithkline Intellectual Property Development Limited Benzimidazole derivatives as bromodomain inhibitors
WO2016168682A2 (en) * 2015-04-15 2016-10-20 Celgene Quanticel Research, Inc. Bromodomain inhibitor
JP2016533397A (ja) * 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
WO2017053243A1 (en) * 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2221692A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
JP3760957B2 (ja) 1996-03-05 2006-03-29 信越化学工業株式会社 新規スルホニウム塩及び化学増幅ポジ型レジスト材料
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
WO2002078625A2 (en) 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
AU2004259755A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
CN1938296A (zh) * 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
KR101352973B1 (ko) 2005-10-26 2014-01-22 삼성에스디아이 주식회사 연료전지용 탈황흡착제 및 이를 이용한 탈황방법
CA2646023A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
GB0919380D0 (en) * 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US8809372B2 (en) * 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
JP6215315B2 (ja) * 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
US9321764B2 (en) 2013-03-12 2016-04-26 Abbvie Inc. Dihydro-pyrrolopyridinone inhibitors
WO2014140077A1 (en) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
MY190835A (en) 2014-01-09 2022-05-12 Orion Corp Bicyclic heterrocyclic derivatives as bromodomain inhibitors
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
JP2018524365A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としての置換アザ化合物
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
EP3484854B1 (en) 2016-07-18 2021-01-20 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
AR111479A1 (es) 2017-04-18 2019-07-17 Celgene Quanticel Res Inc Compuestos derivados de piridina y pirazol
EP3612522A4 (en) * 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6110557A (ja) * 1984-02-22 1986-01-18 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 新規なピリドン化合物
WO1997001551A1 (en) * 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
JP2007538035A (ja) * 2004-05-18 2007-12-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ピリダジノン誘導体、それらの製造法および医薬としてのそれらの使用
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
JP2009507758A (ja) * 2005-09-01 2009-02-26 アステラス製薬株式会社 疼痛の治療に用いられるピリダジノン誘導体
WO2007040208A1 (ja) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2009028543A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
JP2011526282A (ja) * 2008-06-25 2011-10-06 エンビボ ファーマシューティカルズ インコーポレイテッド １，２−二置換複素環式化合物
JP2012515800A (ja) * 2009-01-26 2012-07-12 インターミューン， インコーポレイテッド 急性心筋梗塞および関連障害を処置するための方法
JP2013517244A (ja) * 2010-01-12 2013-05-16 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
JP2016500661A (ja) * 2012-10-02 2016-01-14 インターミューン， インコーポレイテッド 抗線維性ピリジノン
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
WO2014157569A1 (ja) * 2013-03-28 2014-10-02 武田薬品工業株式会社 複素環化合物
JP2016533397A (ja) * 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2016044662A1 (en) * 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
WO2016146738A1 (en) * 2015-03-19 2016-09-22 Glaxosmithkline Intellectual Property Development Limited Benzimidazole derivatives as bromodomain inhibitors
WO2016168682A2 (en) * 2015-04-15 2016-10-20 Celgene Quanticel Research, Inc. Bromodomain inhibitor
WO2017026516A1 (ja) * 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
WO2017053243A1 (en) * 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIDLER, LEWIS R. ET AL: "Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56(20), JPN6022007871, 2013, pages 8073 - 8088, ISSN: 0004880327 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023088901A (ja) * 2017-04-18 2023-06-27 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US11890275B2 (en) 2017-04-18 2024-02-06 Celgene Quanticel Research, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
US11020380B2 (en) 2021-06-01
US10617680B2 (en) 2020-04-14
EP3612522A1 (en) 2020-02-26
US20180296543A1 (en) 2018-10-18
TWI788343B (zh) 2023-01-01
TW202332436A (zh) 2023-08-16
US20210205284A1 (en) 2021-07-08
WO2018195155A1 (en) 2018-10-25
EP3612522A4 (en) 2021-07-07
JP2023088901A (ja) 2023-06-27
US20200163946A1 (en) 2020-05-28
US11890275B2 (en) 2024-02-06
US20240293381A1 (en) 2024-09-05
TW201841900A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
US11884680B2 (en) Bromodomain inhibitors
JP2023088901A (ja) 治療用化合物
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
JP6955482B2 (ja) Ｔｎｆアルファの修飾因子として有用なヘテロ環化合物
KR102699906B1 (ko) 브루톤 티로신 키나제 억제제
AU2017305399A1 (en) Symmetric or semi-symmetric compounds useful as immunomodulators
JP2019513804A (ja) 治療用化合物
WO2008008375A2 (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation
JP2017522346A (ja) ブロモドメインに対して活性な化合物
JP2017500362A (ja) ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
CN113272297B (zh) 作为h4拮抗剂化合物的吡唑衍生物
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
US12552785B2 (en) Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof
CN121311471A (zh) 异喹啉酮衍生物和4h-喹嗪酮衍生物以及其用于治疗疾病的药物组合物
HK1135091B (zh) 三唑基苯基苯磺酰胺
HK1135091A1 (en) Triazolyl phenyl benzenesulfonamides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220926